

Collaborative Staging (CS) for State Reporting



May 20, 2010

Wisconsin Cancer Reporting System


Carole Eberle BS, CTR

Trainer

Topics Covered

- General Information about Staging (Stage of Disease)
- Collaborative Staging (CS)– General Information
- Site Specific Schema
- Required Data Items for State Reporting

Staging in General Stage of Disease

- What It Is
 - Why It Is Used
 - Kinds of Staging Systems
 - Collaborative Efforts
- 

Staging (Stage of Disease)


What It Is

- Describes how much the cancer has spread
- Takes into account
 - Size of Tumor
 - How deeply it has penetrated
 - Whether it has invaded adjacent organs
 - How many lymph nodes (if any) it has spread to
 - Spread to distant organs

Staging (Stage of Disease)

Why It Is Used


- Most powerful predictor of survival—(% survival)



Staging (Stage of Disease)

Why It Is Used

- Treatment Based on Stage



Staging (Stage of Disease)


Kinds (Systems) of Staging Used

- Specific to type (for ex: lung or breast)
- Lymphoma: Ann Arbor Staging
- Hodgkins: I-IV scale or Cotswold System or Modified Ann Arbor Staging System
- Cervical/Ovarian: FIGO system
- Colon: Duke's
- Melanoma: Clark's Level or Breslow Depth
- Prostate: Jewett-Whitmore

Staging (Stage of Disease)

Collaborative Efforts

Most Used Systems

- NCI/SEER → Summary Staging System (currently using Summary Stage 2000 Edition)
 - In-situ
 - Localized
 - Regional
 - Distant
 - AJCC Staging → TNM Staging System (using 7th Edition with 2010 cases)
 - Tumor
 - Nodes
 - Metastasis
- 
- A large, light blue, semi-transparent graphic of two hands shaking is positioned in the lower half of the slide, behind the text. The hands are rendered in a simple, stylized manner, with the fingers slightly curled as if in a firm grip. The background of the entire slide is a light blue gradient.

Staging (Stage of Disease)

Collaborative Efforts

The Value of Each System

- AJCC→TNM
 - Provides forward flexibility and clinical utility for individual cancer cases
 - Dynamic and changes periodically to meet decision-making needs of clinicians regarding appropriate treatment and evaluation of results
- SEER Summary Stage
 - Provides a measure for cancer surveillance for population-based registries
 - Provides meaningful data for analysis for populations, particularly smaller groups of patients
 - Extent of Disease (EOD) coding system provides data that can be used for epidemiological and cancer control studies; it assures consistency over time

Staging (Stage of Disease)

Collaborative Efforts

- Standards Setters
 - National Cancer Institute (NCI)/Surveillance, Epidemiology and End Results (SEER) Program
 - American Joint Committee on Cancer (AJCC)
 - Centers for Disease Control and Prevention/National Program of Cancer Registries (CDC/NPCR)
 - National Cancer Registrars Association (NCRA)
 - North American Association of Central Cancer Registries (NAACCR)
 - American College of Surgeons (ACoS) Commission on Cancer (CoC)

Staging (Stage of Disease)

Collaborative Efforts

- Collaborative Staging Task Force 1998
 - Initial focus was to develop conversion methods between TNM (AJCC) and SEER Summary Stage
 - Eliminate duplicate data collection by registrars for hospitals and other facilities and for central registries
 - Address concerns of clinicians for more clinically relevant data
 - Address public sector's concerns about data reproducibility over time
 - Provide higher degree of compatibility between the systems
 - Expand data sharing opportunities

Staging (Stage of Disease)

Collaborative Efforts

Collaborative Staging System (CSS)

- Carefully selected set of data items that describe how far a cancer has spread at time of diagnosis
- Most of these data items have been collected by cancer registrars and these include: tumor size, extension, lymph node status and metastatic status
- New items were created to collect information necessary for conversion algorithms and these include evaluation fields that describe how the collected data were determined and site/histology factors necessary to derive the final stage grouping
- Additionally, this data set also includes several data items derived from the computer algorithms that classify each case into these multiple staging systems—that is AJCC (TNM) and SEER Summary Staging

Collaborative Staging (CS)

- Version 1 effective with 2004 cases
- Version 2 effective with 2010 cases — CSv2



Collaborative Staging (CS)

Site-Specific Schema

Where to Find

- <http://www.cancerstaging.org/cstage/>
- It will say "Collaborative Stage, Data Collection System"
- On the left, there will be choice called Site Specific Schema, click on that
- There will be several choices, the easiest to use is the Alphabetical Order list, click on that
- Click on the site preference
- Click on the specific element needed, for example: CS Tumor Size or CS Lymph Nodes
- This will give you all the schematic elements and codes for that part of the schema

Collaborative Staging (CS)

Site-Specific Schema

Examples

BREAST

C50.0-C50.6, C50.8-C50.9

C50.0 Nipple

C50.1 Central Portion of Breast

C50.2 Upper inner quadrant of Breast

C50.3 Lower inner quadrant of Breast

C50.4 Upper outer quadrant of Breast

C50.5 Lower outer quadrant of Breast

C50.6 Axillary Tail of Breast

C50.8 Overlapping Lesion of Breast

C50.9 Breast, NOS

Note: Laterality must be coded for this site

CS Tumor Size	Reg LN Exam
CS Extension	CS Mets at Dx
CS Tumor Size/Ext Eval	CS Mets Eval
CS Lymph Nodes	CS Site Specific Factor 1
Reg LN Pos	CS Site Specific Factor 2

Collaborative Stage (CS)

Site-Specific Schema

Examples

Breast

CS Tumor Size

- Note 1 through Note 5:

000	No mass/tumor found
001-988	001-988 millimeters (code exact size in mm)
989	989 millimeters or larger
990	Microinvasion; microscopic focus or foci only, no size given, described as less than 1 mm; stated as T1mi, NOS with no other info on size

Collaborative Stage (CS)

Site-Specific Schema

Site-Specific Factors (SSF)

- Vary for each site
- Some have more than others → BREAST has 24 (which is the most), others may have as few as 2 (for example, LUNG)
- Refers to factors that are specific to the site, for example: ERA test, PRA test which is specific to the breast
- Each factor's value is recorded, for example ERA value for a breast cancer
- These prognostic factors help in determining the stage

Collaborative Staging (CS)

Site-Specific Schema


Where to Find

- <http://www.cancerstaging.org/cstage/>
- It will say "Collaborative Stage, Data Collection System"
- On the left, there will be choice called Site Specific Schema, click on that
- There will be several choices, the easiest to use is the Alphabetical Order list, click on that
- Click on the site preference
- Click on the specific element needed, for example: CS Tumor Size or CS Lymph Nodes
- This will give you all the schematic elements and codes for that part of the schema

Collaborative Stage (CS)

Required Data Items for State Reporting

- Required for ALL sites
 - CS Tumor Size
 - CS Extension
 - CS Tumor Size/Ext Eval
 - CS Lymph Nodes
 - CS Mets at DX



Collaborative Stage (CS)

Required Data Items for State Reporting (works in tandem with CS Mets at DX)

- 4 NEW fields
 - BONE (excluding marrow)
 - LUNG (excluding pleura and pleural fluid)
 - BRAIN (excluding spinal cord and other CNS)
 - LIVER
- Code 0 when CS Mets at DX is 00
- Code Structure
 - 0—No
 - 1—Yes
 - 8—Not Applicable
 - 9--Unknown

Collaborative Stage (CS)

Required Data Items for State Reporting

Site-Specific Factors

- Site Specific Factors (for selected primary sites)
 - Pleura→SSF1
 - Retinoblastoma→SSF1
 - Corpus Adenosarcoma→SSF2
 - Corpus Carcinoma→SSF2
 - Corpus Sarcoma→SSF2
 - Prostate→SSF3
 - Breast→SSF1, SSF2, SSF8, SSF9, SSF10, SSF11, SSF12, SSF13,SSF14
 - NOTE: SSF25 is required for all sites, some sites will be auto filled, other sites the abstractor will need to fill in (see attachment)

CS-Data Items Required for State Reporting


Site-Specific Factor 25

C11.1 All histologies except 8720-8790	C24.0 All histologies	C69.4 8720-8790
C69.5 All histologies	C16.1, C16.2, 8000-8152, 8154-8231, 8243-8245, 8247, 8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701	C48.0-C48.2, C48.8, 8000-8576, 8590-8671, 8930-8934, 8940-9110

CS Data Items for State Reporting

Site Specific Factor 25

Low Probability of Reporting
One Half of One Percent of the Time
($\frac{1}{2}$ of 1%)

A faint, light blue background graphic showing two hands shaking, symbolizing agreement or partnership. The hands are positioned diagonally across the lower half of the slide.

Collaborative Stage (CS)

Required Data Items for State Reporting

What This Means

- When you are abstracting a cancer case, these required data items must be completed
- There are drop down menus which will help
- Primary site code and histology code must be filled in correctly, otherwise the correct menus will not appear

Collaborative Stage (CS)

Required Data Items for State Reporting

Breast Case Scenario

Pathology Report on Lumpectomy for Breast Cancer:
Two millimeter infiltrating duct carcinoma of upper outer quadrant of right breast. The cancer was completely confined to the breast. There were two lymph nodes taken. Immunohistochemistry tests showed the nodes were negative with a HER2 score of 0 (negative). Neither the FISH or CISH tests were done. ERA and PRA were both negative.

Collaborative Stage (CS)

Breast Case Scenario

CS Tumor Size

BREAST

CS Tumor Size

- Note 1 through Note 5:

Code	Description
010	001-988 millimeters (code exact size in millimeters)

Collaborative Stage (CS)

Breast Case Scenario

CS Extension

BREAST

CS Extension

- **Note 1 through Note 7:**

Code	Description	TNM7 MAP	TNM 6MAP	SS77 MAP	SS2000 MAP
100	Confined to breast tissue; Localized NOS			L	L

Collaborative Stage (CS) Breast Case Scenario CS Tumor Size/Ext Eval **BREAST**

Code	Description	Staging Basis
3	Surgical resection performed WITHOUT pre-surgical systemic treatment or radiation	p

Collaborative Stage (CS)

Breast Case Scenario

CS Lymph Nodes

BREAST

CS Lymph Nodes

- Note 1 through Note 7:

Code	Description	TNM 7 MAP	TNM 6 MAP	SS77 MAP	SS2000 MAP
000	None; No LN detected by IHC			None	None

Collaborative Stage (CS)

Breast Case Scenario

CS Mets at DX

BREAST

CS Mets at DX

- Note 1:
- Note 2:

Code	Description	TNM 7 MAP	TNM 6 MAP	SS77 MAP	SS2000 MAP
00	No; None	M0	M0	NONE	NONE

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 1

BREAST

CS Site-Specific Factor 1

Estrogen Receptor Assay (ERA)

- Note 1 through Note 4:

Code	Description
020	Negative/normal; within normal limits

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 2

BREAST

CS Site-Specific Factor 2

Progesterone Receptor Assay (PRA)

- Note 1 through Note 4:

Code	Description
020	Negative/normal; within normal limits

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 8

BREAST

CS Site-Specific Factor 8

HER2: IHC Test Lab Value

- Note 1:
- Note 2:

Code	Description
000	Score 0

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 9

BREAST

CS Site-Specific Factor 9

HER2: IHC Test Interpretation

- **Note 1:**

Code	Description
020	Negative/normal; within normal limits

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 10

BREAST

CS Site-Specific Factor 10

HER2: Fish Test Lab Value

- Note 1 through Note 3:

Code	Description
988	Not applicable; Information not collected for this case

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 11

BREAST

CS Site-Specific Factor 11

HER2: FISH Test Interpretation

- **Note**

Code	Description
988	Not applicable; Information not collected for this case

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 12

BREAST

CS Site-Specific Factor 12

HER2: CISH Test Lab Value

- **Note 1 through Note 3:**

Code	Description
988	Not applicable; Information not collected for this case

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 13

BREAST

CS Site-Specific Factor 13

HER2: CISH Test Interpretation

- **Note**

Code	Description
988	Not applicable; Information not collected for this case

Collaborative Stage (CS)

Breast Case Scenario

CS Site-Specific Factor 14

BREAST

CS Site-Specific Factor 14

HER2: Result of other or unknown test

- **Note**

Code	Description
988	Not applicable; Information not collected for this case

CS Breast Case Scenario Answers

Data Item	Code	Data Item	Code
CS T Size	010	SSF 8	000
CS Ext	100	SSF 9	020
CS TS/Ext Eval	3	SSF 10	988
CS LN	000	SSF 11	988
CS Mets/DX	00	SSF 12	988
SSF 1	020	SSF 13	988
SSF 2	020	SSF 14	988

CS Breast Case Scenario Answers

CS Mets at DX

CS Mets at DX	Bone	0
CS Mets at DX	Lung	0
CS Mets at DX	Liver	0
CS Mets at DX	Brain	0

Collaborative Stage (CS)

Required Data Items for State Reporting

Prostate Case Scenario

This 70 year old male was seen in the doctor's office because of an elevated PSA. DRE revealed an abnormal in size prostate. Prostatic needle core biopsy showed an adenocarcinoma of the prostate. Doctor stated it was a T2 lesion. Two regional nodes were taken for assessment and found to be negative. No other disease progression noted.

Collaborative Stage (CS)

Required Data Items for State Reporting--Prostate Case Scenario

CS Tumor Size

PROSTATE

CS Tumor Size

Code	Description
999	Unknown; size not stated Not documented in patient record

CS-Required Data Items for State Reporting--Prostate Case Scenario

CS Extension-Clinical Extension

PROSTATE

CS Extension—Clinical Extension

- Note 1 through Note 7:

Cod e	Descriptio n	TNM7 MAP	TNM 6 MAP	SS77 MAP	SS2000 MAP
240	Clinically apparent;co n-fined to prostate NOS	T2NOS	T2 NOS	L	L

CS-Required Data Items for State Reporting—Prostate Case Scenario

CS Tumor Size/Ext Eval

PROSTATE

CS Tumor Size/Ext Eval

- Note 1 through Note 9:

Code	Description	Staging Basis
1	Does not meet criteria for path staging; No prostatectomy done; evaluation based on needle core bx, etc	c

CS-Required Data Items for State Reporting-Prostate Case Scenario

CS Lymph Nodes

PROSTATE

CS Lymph Nodes

- Note:

Code	Description	TNM 7MAP	TNM 6MAP	SS77 MAP	SS2000 MAP
000	None; no regional LN involvement	N0	N0	None	None

CS-Required Data Items for State Reporting—Prostate Case Scenario

CS Mets at DX

PROSTATE

CS Mets at DX

Code	Description	TNM 7 MAP	TNM 6 MAP	SS77 MAP	SS2000 MAP
00	No; none	M0	M0	NONE	NONE

CS-Required Data Items for State Reporting—Prostate Case Scenario

CS Site-Specific Factor 3

PROSTATE

CS Site-Specific Factor 3

CS Extension – Pathologic Extension

- Note 1 through Note 10:

Code	Description	TNM 7 MAP	TNM 6 MAP	SS77	SS2000
970	No prostat- ectomy done within 1 st course tx	TX	TX	U	U

CS Prostate Case Scenario Answers

Data Item	Code	Data Item	Code
CS Tumor Size	999	CS Lymph Nodes	000
CS Ext	240	CS Mets at DX	00
CS TS/Ext Eval	1	SSF 3	970

CS-Required Data Items for State Reporting-Prostate Case Scenario

CS Mets at DX—NEW Fields

CS Mets at DX	Bone	0
CS Mets at DX	Lung	0
CS Mets at DX	Liver	0
CS Mets at DX	Brain	0

Collaborative Stage (CS)

Required Data Items for State Reporting—Melanoma Case Scenario

The patient was seen in the dermatologist office for a darkened area on the right upper arm which has been present for about 2 months. Pathology Report (after excision of the area in the doctor's office) showed: a 1 mm malignant melanoma at a Clark's Level I. One area lymph node was taken and it was noted to be negative. No wide excision was necessary, as the whole affected area was removed. No skin graft was necessary. The patient will be followed up in one month and then in 6 month increments.

CS-Required Data Items for State Reporting-Melanoma Case Scenario

CS Tumor Size

MELANOMA SKIN

CS Tumor Size

Code	Description
001	001-988 millimeters (code exact size in millimeters)

CS-Required Data Items for State Reporting-Melanoma Case Scenario

CS Extension

MELANOMA SKIN

CS Extension

- Note 1 through Note 3:

Cod e	Descriptio n	TNM 7 MAP	TNM 6 MAP	SS77 MAP	SS2000 MAP
000	In situ;non invasive; Clark's Level I	Tis	Tis	IS	IS

CS-Required Data Items for State Reporting-Melanoma Case Scenario

CS Tumor Size/Ext Eval

MELANOMA SKIN

CS Tumor Size/Ext Eval

Code	Description	Staging Basis
3	Surgical Resection performed WITHOUT pre-surgical systemic or radiation tx	p

CS-Required Data Items for State Reporting-Melanoma Case Scenario

CS Lymph Nodes

MELANOMA SKIN CS Lymph Nodes

- Note 1: Note 3:
- Note 2: Note 4:

Code	Description	TNM 7 MAP	TNM 6 MAP	SS77 MAP	SS2000 MAP
000	None; no regional LN involvement	N0	N0	NONE	NONE

CS-Required Data Items for State Reporting-Melanoma Case Scenario

CS Mets at DX

MELANOMA SKIN

CS Mets at DX

Code	Description	TNM 7 MAP	TNM 6 MAP	SS77 MAP	SS2000 MAP
00	No; none	M0	M0	NONE	NONE

Melanoma Case Scenario

Answers

Data Item	Code	Data Item	Code
CS Tumor Size	001	CS Lymph Nodes	000
CS Ext	000	CS Mets at DX	00
CS Tumor Size/Ext Eval	3		

CS Melanoma Case Scenario

CS Mets at DX

CS Mets at DX	Bone	0
CS Mets at DX	Lung	0
CS Mets at DX	Liver	0
CS Mets at DX	Brain	0

Questions

carolynn.eberle@dhs.wi.gov

A stylized illustration of two hands shaking, rendered in a light blue and white color scheme. The hands are positioned horizontally across the lower half of the slide, with the left hand on the left and the right hand on the right. The background is a light blue gradient.

Questions

www.DHS.wisconsin.gov/wcrs



Collaborative Stage Schema Website

<http://www.cancerstaging.org/cstage>



**Remember,
This is a collaborative effort.
TOGETHER
We can all help our Cancer Patients**

